Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ARGX
ARGENX SE
NASDAQ
$1023.21
▼ DOWN 3.37% (-35.69)

KEY STATISTICS

Market Cap$63.63 B
52w High$1061.57
52w Low$661.85
Dividend Yield—
Frequency—
P/E92.35
Volume175.51K
Shares Out.62.19M

COMPANY

LEADERSHIP

Karen Massey
CHIEF EXECUTIVE
Karen Massey

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 18, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,863

PRICE TARGET

Target High$1415.00
Target Low$932.00
Target Median$1167.50
Target Consensus$1163.86

UPCOMING EARNINGS

DateMar 4, 2027
DayThursday
Rev. Est.$3.35B
MAR
4
THU

PRICE

$1023.21 ▼ DOWN 3.37% (−$35.69)
$1020$1030$1040$10509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1023.21

About argenx SE

https://www.argenx.com ↗

argenx SE, a Netherlands-based biotech founded in 2008, develops therapies for autoimmune diseases worldwide, with lead products like efgartigimod and VYVGART, collaborating globally with partners such as AbbVie and Genmab.

INDUSTRY

Biotechnology

A PRODUCT ARGENX SE IS KNOWN FOR

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

VYVGART Hytrulo by argenx SE is the first approved neonatal Fc receptor (FcRn) blocker, administered via subcutaneous injection, for treating adult generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).

COMPETITORS

COMPETITOR
AZN COMPARE
BIIB COMPARE
GSK COMPARE
IMVT COMPARE
JNJ COMPARE

Revenue by Geography

MapREGIONQ2-2021Q2-2022Q2-2023Q4-2023
UNITED STATES— $94.35M $440.85M ▲$605.74M ▲
U$317.26M — — —
C$151.9M — — —
EMEA— — $22.84M $50.02M ▲
JAPAN— $1.51M $23.64M ▲$32.79M ▲
Countries Other Than United States And China$1.24M — — —
Other— $133K — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
113
LISTED HERE
26
RANKED BY POSITION SIZE
IBB
3.64% · 387.7K
SCHF
0.21% · 140.7K
CGGO
1.01% · 114.9K
FBT
3.65% · 103.2K
SPDW
0.19% · 75.1K
AVDE
0.16% · 29.9K
BBH
4.77% · 21.6K
DFAI
0.09% · 16.0K
FENI
0.11% · 12.0K
PRIZ.L
0.86% · 10.2K
TGRT
0.57% · 8.6K
FDG
1.38% · 6.1K
CN
CNCR
3.42% · 5.1K
LGEG.L
0.61% · 3.1K
EXUS
3.14% · 3.0K
GSID
0.28% · 3.0K
PR
PRAE
0.40% · 2.8K
PJIO
4.78% · 2.8K
IQSI
0.42% · 1.1K
FF
FFND
1.12% · 1.1K
BIB
1.00% · 988
NTSI
0.20% · 951
MNTL
5.83% · 890
AFTY
0.88% · 847
JHMD
0.06% · 597
QQQN
1.77% · 568

INSTITUTIONAL OWNERSHIP

SHARES OWNED
36.29%
HOLDERS
691
TOP 12 OF 691 · RANKED BY POSITION SIZE
Fmr LLC
5.7M sh · $4.2B
Price T Rowe Associates Inc /Md/
3.6M sh · $2.69B
Janus Henderson Group Plc
2.6M sh · $1.9B
Capital World Investors
2.3M sh · $1.65B
Artisan Partners Limited Partnership
2.2M sh · $1.61B
Wellington Management Group Llp
1.0M sh · $745.92M
Blackrock Inc.
1.0M sh · $434.9M
Avoro Capital Advisors LLC
1.0M sh · $927.77M
Bb Biotech AG
904.7K sh · $112.95M
Blackrock, Inc.
808.3K sh · $590.29M
Clearbridge Investments, LLC
756.9K sh · $558.23M
Citadel Advisors LLC
713.6K sh · $526.29M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-07-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OUTPERFORM 4
OVERWEIGHT 4
MARKET OUTPERFORM 1
NEUTRAL 1
PEER PERFORM 1
18 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Wedbush OUTPERFORM Truist Securities BUY HC Wainwright & Co. BUY RBC Capital OUTPERFORM Morgan Stanley OVERWEIGHT Piper Sandler OVERWEIGHT Baird NEUTRAL

SECTORS PEERS

PEERPRICE
REGN$794.19COMPARE
CAH$234.55COMPARE
BDX$189.52COMPARE
EW$90.21COMPARE
VEEV$276.69COMPARE
HLN$10.11COMPARE
IDXX$554.99COMPARE
A$153.85COMPARE